Slide background

At the forefront of ophthalmic innovation and
leading the movement toward safer, easier to administer
treatments for ophthalmic conditions

Learn More
Slide background

Novel technologies that offer a variety of benefits
to patients and clinicians, as well as potential pharma partners.

Learn More
Slide background

A potential alternative to current delivery modalities
to overcome many of the key limitations
of existing delivery methods.

Learn More

Superior Treatment Options

EyeGate Pharma (NASDAQ: EYEG) is a late-stage clinical company focused on developing for treating disorders of the eye. EyeGate’s lead product, Ocular Bandage Gel (“OBG”), is based on a modified form of the natural polymer hyaluronic acid. The product is applied as a clear topical gel, to the damaged ocular surface and possesses unique properties that help hydrate, protect, and heal the ocular surface. EyeGate is in the clinic for two different patient populations: (1) photorefractive keratectomy (“PRK”) surgery to demonstrate corneal wound repair after refractive surgery; and (2) punctate epitheliopathies (“PE”), specifically in patients with dry eye.